DE69301750D1 - Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose - Google Patents

Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose

Info

Publication number
DE69301750D1
DE69301750D1 DE69301750T DE69301750T DE69301750D1 DE 69301750 D1 DE69301750 D1 DE 69301750D1 DE 69301750 T DE69301750 T DE 69301750T DE 69301750 T DE69301750 T DE 69301750T DE 69301750 D1 DE69301750 D1 DE 69301750D1
Authority
DE
Germany
Prior art keywords
dihydroxy
alpha
osteoporosis
dehydrovitamin
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69301750T
Other languages
English (en)
Other versions
DE69301750T2 (de
Inventor
Hector Floyd Deluca
Heinrich Konstantine Schnoes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Application granted granted Critical
Publication of DE69301750D1 publication Critical patent/DE69301750D1/de
Publication of DE69301750T2 publication Critical patent/DE69301750T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69301750T 1992-04-24 1993-04-26 Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose Expired - Fee Related DE69301750T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87337492A 1992-04-24 1992-04-24

Publications (2)

Publication Number Publication Date
DE69301750D1 true DE69301750D1 (de) 1996-04-18
DE69301750T2 DE69301750T2 (de) 1996-07-25

Family

ID=25361517

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69301750T Expired - Fee Related DE69301750T2 (de) 1992-04-24 1993-04-26 Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose

Country Status (10)

Country Link
US (1) US5395830A (de)
EP (1) EP0567352B1 (de)
JP (1) JP2769960B2 (de)
KR (1) KR940005275A (de)
AT (1) ATE135220T1 (de)
AU (1) AU666529B2 (de)
CA (1) CA2094424C (de)
DE (1) DE69301750T2 (de)
IL (1) IL105475A (de)
NZ (1) NZ247406A (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US5661140A (en) * 1994-11-21 1997-08-26 Wisconsin Alumni Research Foundation 18-nor-vitamin D compounds
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
KR100474517B1 (ko) * 1997-10-27 2005-07-21 삼성전자주식회사 엘씨디패널절단장치
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
AU7706800A (en) * 1999-09-24 2001-04-30 Quing Non Yng-Wong Delivery of small doses of ingestible treatments
US20060135491A1 (en) * 2004-12-06 2006-06-22 Roger Bouillon Vitamin D3 analog useful for the treatment of osteoporosis
DK1993375T3 (en) 2006-03-10 2017-07-17 Dsm Ip Assets Bv Hitherto UNKNOWN USE OF NUTRACEUTIC COMPOSITIONS IN ANIMAL FEED.
SG2014006324A (en) * 2009-01-27 2014-03-28 Berg Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
CN106265695B (zh) 2009-08-14 2021-05-07 博格有限责任公司 用于治疗脱发的维生素d3及其类似物
NZ714801A (en) 2013-05-29 2021-07-30 Berg Llc Preventing or mitigating chemotherapy induced alopecia using vitamin d

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833622A (en) * 1969-03-17 1974-09-03 Upjohn Co Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds
US3901928A (en) * 1973-01-10 1975-08-26 Robert Henry Hesse 1' ,3' -dihydroxy steroid-5-enes method of preparing same and their use for preparing 1' -hydroxy-25-hydrogen vitamin d compounds
US4260549A (en) * 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4267117A (en) * 1978-06-19 1981-05-12 The Upjohn Company Compounds and process
US4255596A (en) * 1980-02-25 1981-03-10 Gulf Research & Development Company Preparation of ethylene glycol from ethylene
JPS6089422A (ja) * 1983-10-24 1985-05-20 Kureha Chem Ind Co Ltd 抗骨粗鬆症剤
US4719204A (en) * 1984-03-05 1988-01-12 Wisconsin Alumni Research Foundation Fowl bone mineralization with 28-NOR 1α-hydroxyvitamin D2 analogs
US4588716A (en) * 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
US4588528A (en) * 1984-05-31 1986-05-13 Wisconsin Alumni Research Foundation 1,24-dihydroxy-Δ22 -vitamin D3 and process for preparing same
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US5001118A (en) * 1986-12-29 1991-03-19 Kureha Kagaku Kogyo Kabushiki Kaisha Method for preventing senescence and increasing bone mass
US4997824A (en) * 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
US5053401A (en) * 1989-02-28 1991-10-01 Chugai Seiyaku Kabushiki Kaisha Osteogenesis promotion with use of vitamin d derivatives

Also Published As

Publication number Publication date
EP0567352B1 (de) 1996-03-13
ATE135220T1 (de) 1996-03-15
US5395830A (en) 1995-03-07
IL105475A (en) 1997-06-10
KR940005275A (ko) 1994-03-21
JP2769960B2 (ja) 1998-06-25
DE69301750T2 (de) 1996-07-25
JPH0624992A (ja) 1994-02-01
CA2094424C (en) 2001-01-02
IL105475A0 (en) 1993-08-18
AU3689193A (en) 1993-10-28
CA2094424A1 (en) 1993-10-25
EP0567352A1 (de) 1993-10-27
NZ247406A (en) 1999-05-28
AU666529B2 (en) 1996-02-15

Similar Documents

Publication Publication Date Title
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DE122005000002I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
ATE359074T1 (de) Raloxifene in der behandlung von postmeopausal osteoporose
DE69010162T2 (de) Zusammensetzung zur Behandlung von Entzündung.
ATE141505T1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE69301750T2 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
DE3854121T2 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
DE69026511T2 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
DE3768150D1 (de) Verwendung eines 1,3-oxazolidin-2-on-derivates zur herstellung eines arzneimittels zur behandlung von ischaemie.
DE3686097T2 (de) Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht.
DE68916777D1 (de) Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
PT76582A (de) 1,2,4-triazol-1-yl-propionitrile verfahren zur herstellung dieser verbindungen sowie diese enthaltende biozide mittel
DE69307197T2 (de) Verwendung von 24,25-Dihydroxyvitamin-D3 zur Herstellung eines Arzneimittel zur Behandlung der Rachitis
DE3585312D1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
DE69516602T2 (de) Verwendung von Bifemelan zur Herstellung eines Arzneimittels zur Behandlung der Hyperkinesie
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE69022027T2 (de) 2-Alkyl-3-benzoylbenzofurane zur Behandlung von Herzarrhythmia.
DE69228235T2 (de) Verwendung eines Mittels zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankung
DE69830811D1 (de) Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis
DE69215191D1 (de) Verwendung von thiol-5-(2-diethyl-aminoethyl)-ester-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung der neuromuskuläre Inkontinenz
ATE150645T1 (de) Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee